DRD2 and Parkinson disease: In support of our hypothesis that D2R agonists inhibit SCLC growth by reducing tumour angiogenesis, a meta-analysis of 348,780 patients with Parkinson’s disease showed that patients who received dopaminergic therapy for the Parkinson’s had a 47% reduction in risk of developing lung cancer [81].